3,779 Shares in Sanofi (NASDAQ:SNY) Acquired by Nikulski Financial Inc.

Nikulski Financial Inc. bought a new position in shares of Sanofi (NASDAQ:SNY) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,779 shares of the company’s stock, valued at approximately $218,000.

Several other institutional investors and hedge funds have also made changes to their positions in SNY. Manning & Napier Advisors LLC purchased a new position in Sanofi during the 2nd quarter valued at about $13,725,000. Mount Yale Investment Advisors LLC grew its stake in Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after purchasing an additional 12,806 shares in the last quarter. Jennison Associates LLC increased its holdings in Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after purchasing an additional 30,115 shares during the period. Sei Investments Co. raised its position in Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after purchasing an additional 47,297 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in Sanofi by 10.4% in the first quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company’s stock worth $14,951,000 after acquiring an additional 29,082 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SNY shares. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $57.50.

Sanofi Stock Performance

SNY traded down $0.48 during trading on Thursday, hitting $52.97. The stock had a trading volume of 28,134 shares, compared to its average volume of 2,032,605. Sanofi has a twelve month low of $45.00 and a twelve month high of $58.97. The firm has a market capitalization of $134.43 billion, a P/E ratio of 27.27, a PEG ratio of 1.55 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company’s 50-day moving average price is $56.02 and its 200 day moving average price is $51.91.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the company earned $2.55 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, equities research analysts forecast that Sanofi will post 4.25 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.